EGRX vs. HCWB, CKPT, VHAQ, GMTX, LTRN, KZR, EQ, KRON, MRNS, and VAXX
Should you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include HCW Biologics (HCWB), Checkpoint Therapeutics (CKPT), Viveon Health Acquisition (VHAQ), Gemini Therapeutics (GMTX), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), Equillium (EQ), Kronos Bio (KRON), Marinus Pharmaceuticals (MRNS), and Vaxxinity (VAXX). These companies are all part of the "pharmaceutical preparations" industry.
HCW Biologics (NASDAQ:HCWB) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk.
Eagle Pharmaceuticals has a net margin of 0.00% compared to Eagle Pharmaceuticals' net margin of -879.49%. HCW Biologics' return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
Eagle Pharmaceuticals has higher revenue and earnings than HCW Biologics. HCW Biologics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
HCW Biologics has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Eagle Pharmaceuticals received 406 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 70.79% of users gave Eagle Pharmaceuticals an outperform vote.
Eagle Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 273.63%. Given HCW Biologics' higher probable upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than HCW Biologics.
In the previous week, HCW Biologics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for HCW Biologics and 0 mentions for Eagle Pharmaceuticals. Eagle Pharmaceuticals' average media sentiment score of 0.59 equaled HCW Biologics'average media sentiment score.
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 45.3% of HCW Biologics shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Eagle Pharmaceuticals beats HCW Biologics on 10 of the 15 factors compared between the two stocks.
Get Eagle Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eagle Pharmaceuticals Competitors List
Related Companies and Tools
